Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the 45th Annual TD Cowen Healthcare Conference scheduled for March 3-5, 2025, in Boston, MA.

The company will provide a live audio webcast of their presentation, which will be accessible through the 'Investors' section of Xenon's website, with a replay option available post-event.

Xenon specializes in developing ion channel products targeting epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.

News Market Reaction – XENE

+3.85%

1 alert

+3.85% News Effect

On the day this news was published, XENE gained 3.85%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025.

Fireside Chat Presentation Details:
Date:	Tuesday, March 4, 2025
Time:	10:30-11:00 AM Eastern Time
Webcast:	Register here
Presenters:	Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financial Officer

A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When is Xenon Pharmaceuticals (XENE) presenting at the TD Cowen Healthcare Conference 2025?

Xenon Pharmaceuticals will present at the TD Cowen Healthcare Conference between March 3-5, 2025, in Boston, MA.

What is azetukalner and what is its development status for XENE?

Azetukalner is a novel Kv7 potassium channel opener, currently in late-stage clinical development for multiple indications, representing Xenon's most advanced potassium channel modulator.

Which therapeutic areas does XENE focus on in their drug development pipeline?

Xenon Pharmaceuticals focuses on developing treatments for epilepsy and depression through their ion channel product portfolio.

How can investors access Xenon's presentation at the TD Cowen Healthcare Conference?

Investors can access a live audio webcast of the presentation through the 'Investors' section of Xenon's website, with replay available after the event.